Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα [tumour necrosis factor alpha] Inhibitor Therapy

Next Previous
Search
Trial Profile

A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα [tumour necrosis factor alpha] Inhibitor Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Acronyms BCDG
  • Sponsors Eli Lilly and Company (India) Pvt. Ltd

    • Most Recent Events

    • 28 May 2011 Primary endpoint 'American-College-of-Rheumatology-50%-response-criteria' has not been met, according to results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 19 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top